Remimazolam to prevent hemodynamic instability during catheter ablation under general anesthesia: a randomized controlled trial
ConclusionsRemimazolam was a viable option for general anesthesia for cardiac ablation. Remimazolam-based total intravenous anesthesia was associated with significantly fewer hypotensive events and vasopressor requirements than desflurane-based inhalational anesthesia was, without significantly more complications.Study registrationClinicalTrials.gov (NCT05486377); first submitted 1 August 2022.
Source: Canadian Journal of Anesthesia - Category: Anesthesiology Source Type: research
More News: Anesthesia | Anesthesiology | Arrhythmia | Canada Health | Clinical Trials | Diprivan | Eyes | Pain | Propofol | Study